Methods
This single-center randomized controlled trial enrolled children between
1-144 months of age who were admitted to the intensive care unit of the
Capital Institute of Pediatrics over a period of 36 months (June 1,
2017–June 1, 2020), and required vancomycin therapy. These children
were randomly assigned to the CIV and IIV groups. The demographic, index
of PK/PD such as the ratio of the area under the concentration-time
curve over 24 h [AUC0–24h] to the minimum
inhibitory concentration [AUC0–24h/MIC]), outcomes,
and drug-related adverse effects were collected and analyzed.